Drug intelligence / Profile preview

IQP-AE-103

Development stage
Unknown
Lead developer
InQpharm
Modality
Small Molecules
Administration
Oral
01

Overview

IQP-AE-103 is a proprietary, orally administered weight loss intervention composed primarily of okra (Abelmoschus esculentus) pod powder and inulin. It is designed as a natural agent to aid in weight management for overweight and moderately obese adults. The formulation leverages the fat-binding properties of soluble dietary fibers from okra and inulin to reduce calorie intake, decrease absorption of dietary fat, and promote satiety. Clinical studies have demonstrated that high-dose IQP-AE-103 leads to significant reductions in body weight, body fat, waist circumference, and feelings of hunger compared with placebo over 12 weeks. Additionally, it has shown beneficial effects on lipid metabolism and positive modulation of gut microbiota composition—specifically increasing Akkermansia muciniphila abundance while reducing Firmicutes—among responders who lost at least 5% body weight[1][2][6][7]. No significant adverse events have been reported.

Brand names
IQP-AE-103IQP-AE103IQP-AE 103

Beyond the preview

Go deeper on IQP-AE-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IQP-AE-103.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call